Navigation Links
UCLA researchers design nanomachine that kills cancer cells

Researchers from the Nano Machine Center at the California NanoSystems Institute at UCLA have developed a novel type of nanomachine that can capture and store anticancer drugs inside tiny pores and release them into cancer cells in response to light.

Known as a "nanoimpeller," the device is the first light-powered nanomachine that operates inside a living cell, a development that has strong implications for cancer treatment.

UCLA researchers reported the synthesis and operation of nanoparticles containing nanoimpellers that can deliver anticancer drugs March 31 in the online edition of the nanoscience journal Small.

The study was conducted jointly by Jeffrey Zink, UCLA professor of chemistry and biochemistry, and Fuyu Tamanoi, UCLA professor of microbiology, immunology and molecular genetics and director of the signal transduction and therapeutics program at UCLA's Jonsson Comprehensive Cancer Center. Tamanoi and Zink are two of the co-directors for the Nano Machine Center for Targeted Delivery and On-Demand Release at the California NanoSystems Institute.

Nanomechanical systems designed to trap and release molecules from pores in response to a stimulus have been the subject of intensive investigation, in large part for their potential applications in precise drug delivery. Nanomaterials suitable for this type of operation must consist of both an appropriate container and a photo-activated moving component.

To achieve this, the UCLA researchers used mesoporous silica nanoparticles and coated the interiors of the pores with azobenzene, a chemical that can oscillate between two different conformations upon light exposure. Operation of the nanoimpeller was demonstrated using a variety of human cancer cells, including colon and pancreatic cancer cells. The nanoparticles were given to human cancer cells in vitro and taken up in the dark. When light was directed at the particles, the nanoimpeller mechanism took effect and released the contents.

The pores of the particles can be loaded with cargo molecules, such as dyes or anticancer drugs. In response to light exposure, a wagging motion occurs, causing the cargo molecules to escape from the pores and attack the cell. Confocal microscopic images showed that the impeller operation can be regulated precisely by the intensity of the light, the excitation time and the specific wavelength.

"We developed a mechanism that releases small molecules in aqueous and biological environments during exposure to light," Zink said. "The nanomachines are positioned in molecular-sized pores inside of spherical particles and function in aqueous and biological environments."

"The achievement here is gaining precise control of the amount of drugs that are released by controlling the light exposure," Tamanoi said. "Controlled release to a specific location is the key issue. And the release is only activated by where the light is shining."

"We were extremely excited to discover that the machines were taken up by the cancer cells and that they responded to the light. We observed cell killing as a result of programmed cell death," Tamanoi and Zink said.

This nanoimpeller system may open a new avenue for drug delivery under external control at specific times and locations for phototherapy. Remote-control manipulation of the machine is achieved by varying both the light intensity and the time that the particles are irradiated at the specific wavelengths at which the azobenzene impellers absorb.

"This system has potential applications for precise drug delivery and might be the next generation for novel platform for the treatment of cancers such as colon and stomach cancer," Zink and Tamanoi said. "The fact that one can operate the mechanism by remote control means that one can administer repeated small-dosage releases to achieve greater control of the drug's effect."

Tamanoi and Zink say the research represents an exciting first step in developing nanomachines for cancer therapy and that further steps are required to demonstrate actual inhibition of tumor growth.


Contact: Jennifer Marcus
University of California - Los Angeles

Related medicine news :

1. Researchers study why high school boys dodge Phys Ed
2. Researchers Successfully Test Ebola Vaccines
3. Researchers identify a gene responsible for cases of Lou Gehrigs disease
4. Researchers identify a gene responsible for Lou Gehrigs disease
5. UCLA researchers examine human embryonic stem cell genome
6. Researchers Create Protective Sac for Growing Stem Cells
7. UC Irvine researchers present latest findings at emergency medicine forum
8. Researchers urge ethics guidelines for human-genome research
9. OHSU Cancer Institute researchers identify new approach to help control drug resistance in leukemia
10. NYU dental researchers find evidence of periodontal disease leading to gestational diabetes
11. Researchers Gain Insights Into On-Off Switch for Cells
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, the leading ... with Tennessee Counseling Association. This new relationship allows TherapySites to continue ... Association, adding exclusive benefits and promotional offers. , "TCA is extremely excited about ...
(Date:6/26/2016)... ... 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic ... World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. ... some of the world’s leading providers of cereal and other breakfast foods. Its residents ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology: